CBAY News and Press, CymaBay Therapeutics Inc. From 03/17/22

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to it...

CymaBay Therapeutics press release (NASDAQ:CBAY): Q4 GAAP EPS of -$0.34 misses by $0.11. The company had $194.6M in cash, cash equivalents and short-term investments as of December 31, 2021. For further details see: CymaBay Therapeutics GAAP EPS of -$0.34 misses by $0.11

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the...

CymaBay Therapeutics (NASDAQ:CBAY) is scheduled to announce Q4 earnings results on Thursday, March 17th, after market close. The consensus EPS Estimate is -$0.20 (+13.0% Y/Y) and the consensus Revenue Estimate is $7.5M For further details see: CymaBay Therapeutics Q4 2021 Earnings Previ...

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live au...

100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...

CymaBay Therapeutics (NASDAQ:CBAY) has priced its previously announced public offering of common stock and pre-funded warrants. The firm is offering 15,625,000 shares of common stock and pre-funded warrants to purchase 3,125,000 shares of common stock. The common shares are being sold at $4.0...

NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today a...

CymaBay Therapeutics (NASDAQ:CBAY) is trading flat in the post-market after the company announced the start of an underwritten public offering of common stock and pre-funded warrants. A 30-day option allowing underwriters to purchase an additional 15% of the shares of the common stock is also...